164 related articles for article (PubMed ID: 38582965)
1. Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
Ahn T; Bae EA; Seo H
Mol Ther; 2024 Jun; 32(6):1617-1627. PubMed ID: 38582965
[TBL] [Abstract][Full Text] [Related]
2. Engineering chimeric antigen receptor-T cells for cancer treatment.
Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
[TBL] [Abstract][Full Text] [Related]
3. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling.
Weber EW; Parker KR; Sotillo E; Lynn RC; Anbunathan H; Lattin J; Good Z; Belk JA; Daniel B; Klysz D; Malipatlolla M; Xu P; Bashti M; Heitzeneder S; Labanieh L; Vandris P; Majzner RG; Qi Y; Sandor K; Chen LC; Prabhu S; Gentles AJ; Wandless TJ; Satpathy AT; Chang HY; Mackall CL
Science; 2021 Apr; 372(6537):. PubMed ID: 33795428
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
5. Exhausted T cells and epigenetic status.
Zeng Z; Wei F; Ren X
Cancer Biol Med; 2020 Nov; 17(4):923-936. PubMed ID: 33299644
[TBL] [Abstract][Full Text] [Related]
6. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
7. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
8. BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.
Kong W; Dimitri A; Wang W; Jung IY; Ott CJ; Fasolino M; Wang Y; Kulikovskaya I; Gupta M; Yoder T; DeNizio JE; Everett JK; Williams EF; Xu J; Scholler J; Reich TJ; Bhoj VG; Haines KM; Maus MV; Melenhorst JJ; Young RM; Jadlowsky JK; Marcucci KT; Bradner JE; Levine BL; Porter DL; Bushman FD; Kohli RM; June CH; Davis MM; Lacey SF; Vahedi G; Fraietta JA
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396987
[TBL] [Abstract][Full Text] [Related]
9. TET2 guards against unchecked BATF3-induced CAR T cell expansion.
Jain N; Zhao Z; Feucht J; Koche R; Iyer A; Dobrin A; Mansilla-Soto J; Yang J; Zhan Y; Lopez M; Gunset G; Sadelain M
Nature; 2023 Mar; 615(7951):315-322. PubMed ID: 36755094
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic engineering for optimal chimeric antigen receptor T cell therapy.
Ito Y; Kagoya Y
Cancer Sci; 2022 Nov; 113(11):3664-3671. PubMed ID: 36000807
[TBL] [Abstract][Full Text] [Related]
11. Developmental Relationships of Four Exhausted CD8
Beltra JC; Manne S; Abdel-Hakeem MS; Kurachi M; Giles JR; Chen Z; Casella V; Ngiow SF; Khan O; Huang YJ; Yan P; Nzingha K; Xu W; Amaravadi RK; Xu X; Karakousis GC; Mitchell TC; Schuchter LM; Huang AC; Wherry EJ
Immunity; 2020 May; 52(5):825-841.e8. PubMed ID: 32396847
[TBL] [Abstract][Full Text] [Related]
12. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
13. Transcription factors in chimeric antigen receptor T-cell development.
Dai A; Zhang X; Wang X; Liu G; Wang Q; Yu F
Hum Cell; 2024 May; 37(3):571-581. PubMed ID: 38436882
[TBL] [Abstract][Full Text] [Related]
14. Generation of CAR-T
Hu J; Liu X
Int Immunopharmacol; 2024 Jul; 136():112379. PubMed ID: 38833844
[TBL] [Abstract][Full Text] [Related]
15. Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.
Fisher J; Sharma R; Don DW; Barisa M; Hurtado MO; Abramowski P; Porter L; Day W; Borea R; Inglott S; Anderson J; Pe'er D
Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506382
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic strategies to boost CAR T cell therapy.
Akbari B; Ghahri-Saremi N; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Mol Ther; 2021 Sep; 29(9):2640-2659. PubMed ID: 34365035
[TBL] [Abstract][Full Text] [Related]
17. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity.
Prinzing B; Zebley CC; Petersen CT; Fan Y; Anido AA; Yi Z; Nguyen P; Houke H; Bell M; Haydar D; Brown C; Boi SK; Alli S; Crawford JC; Riberdy JM; Park JJ; Zhou S; Velasquez MP; DeRenzo C; Lazzarotto CR; Tsai SQ; Vogel P; Pruett-Miller SM; Langfitt DM; Gottschalk S; Youngblood B; Krenciute G
Sci Transl Med; 2021 Nov; 13(620):eabh0272. PubMed ID: 34788079
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.
Shen C; Zhang Z; Zhang Y
Biomed Res Int; 2020; 2020():8765028. PubMed ID: 33150182
[TBL] [Abstract][Full Text] [Related]
19. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
Yin X; He L; Guo Z
Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
[TBL] [Abstract][Full Text] [Related]
20. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
Sloas C; Gill S; Klichinsky M
Front Immunol; 2021; 12():783305. PubMed ID: 34899748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]